AstraZeneca Canada Inc., in consultation with Health Canada, has issued important safety information on PULMICORT TURBUH
- PDF / 136,405 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 48 Downloads / 166 Views
1
■ AstraZeneca Canada Inc., in consultation with Health Canada, has issued important safety information on PULMICORT TURBUHALER
[budesonide] powder for oral inhalation, 200 µg per metered dose. The company has received a small number of product complaints relating to a malfunction of the delivery device resulting in failure to dispense the dose of medication. The patient will not hear the "click" sound when the ’turn grip’ is rotated, and the intended dose will not be loaded into the unit. Health Care Professionals are advised to discuss and reinforce with their patients the proper use of the device (TURN, CLICK, INHALE), as described in the Consumer Information Leaflet. Any case of adverse reactions in patients receiving PULMICORT TURBUHALER should be reported to the company or to Health Canada. Maresky N. Health Canada Endorsed Important Safety Information on PULMICORT TURBUHALER (budesonide) powder for oral inhalation, 200 microg per metered dose. Internet Document : [2 pages], 23 Jul 2012. 803074731 Available from: URL: http://www.hc-sc.gc.ca
0114-9954/10/1413-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 4 Aug 2012 No. 1413
Data Loading...
